ESTRO 2024 - Abstract Book

S740

Clinical - CNS

ESTRO 2024

Conclusion:

Sarcopenia is an independent marker of poor prognosis in NSCLC patients with BMs, who were treated with GKRS.

Keywords: Sarcopenia, Gamma Knife, Brain metastases

59

Digital Poster

Lower NANO criteria are associated better response to GKRS treatment of meningiomas

Ivaylo Stanimirov Petrov 1 , Manoela Krasteva Cholakova 1 , Ivo Plamenov Petrov 2 , Bilyana Georgieva Korabova 1 , Nikola Nikolaev Bildirev 1 , Roumen Metodiev Lazarov 1 , Iglika Spasova Mihaylova 3 , Kiril Zhelev Zhelev 1 1 MHAT Heart and Brain, Radiotherapy and Radiosurgery, Pleven, Bulgaria. 2 MHAT Heart and Brain, Medical Physics, Pleven, Bulgaria. 3 SHAT in Oncology, Radiotherapy, Sofia, Bulgaria

Purpose/Objective:

Response assessment in neuro-oncology (RANO) criteria were developed to enhance the assessment of tumor response and provide guidance for the assessment of response and endpoints in clinical trials of neuro-oncology. Neurologic assessment in neuro-oncology (NANO) scale is a tool used to assess neurological function objectively and practically in intracranial tumor patients. This single retrospective study sought to determine the relationship between RANO criteria and clinical outcome as measured by the NANO scale in patients with intracranial meningioma treated only with Gamma Knife radiosurgery (GKRS).

Material/Methods:

Data of 44 patients with intracranial meningioma who were treated with GKRS in MHAT „Heart and Brain “ - Pleven between January 2020 and August 2023 were retrospectively analyzed. The RANO criteria were obtained by comparing the size of the enhanced lesion using contrast-enhanced T1-weighted Magnetic Resonance Imaging (MRI) images within an interval of a minimum of six months after treatment. The NANO scale is a quantitative examination-based evaluation of nine pertinent neurologic domains. As assessed domains from the medical record, the NANO scale included gait, strength, ataxia, sensation, visual fields, facial strength, language, level of consciousness, and behavior. The cut off value of NANO scale (≤2) was used to divide patients into patients with or without neurological symptoms. Overall response rate (ORR) is the proportion of patients who had a partial, complete, or minor response to the treatment. The main dose regimen was 12Gy range (9-25Gy) delivered in 1 fraction range (1-5fr.), with the median dose of tumor volume (TV) being 24Gy and the prescription to 50% isodose.

Results: